Comparative Pharmacology
Head-to-head clinical analysis: LOPROX versus MONISTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOPROX versus MONISTAT.
LOPROX vs MONISTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciclopirox is a hydroxypyridone antifungal agent that inhibits metal-dependent enzymes, including cytochromes, by chelating polyvalent cations (Fe3+, Al3+). It disrupts fungal cell membrane integrity and mitochondrial electron transport, leading to fungicidal activity. It also has anti-inflammatory properties by inhibiting prostaglandin and leukotriene synthesis.
Miconazole, the active ingredient in MONISTAT, inhibits fungal CYP51 (lanosterol 14-alpha-demethylase), blocking ergosterol synthesis and disrupting fungal cell membrane integrity, leading to cell death.
Ciclopirox 1% cream or lotion: apply to affected area twice daily. Nail lacquer (8%): apply to affected nails daily. Shampoo (1%): apply 5-10 mL to wet scalp, lather, leave for 3 minutes, rinse; use twice weekly.
Intravaginal: 200 mg suppository at bedtime for 3 days, or 100 mg suppository at bedtime for 7 days, or 2% cream 5 g intravaginally at bedtime for 7 days. Topical: Apply 2% cream twice daily for 2-4 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 1.7 hours for the absorbed fraction, reflecting rapid renal clearance.
Approximately 90-120 minutes; supports twice-daily local dosing.
Less than 1% of topically applied ciclopirox is absorbed; absorbed drug is conjugated and excreted renally as glucuronides, with minor fecal elimination.
Primarily fecal (approximately 90%) as unchanged drug; less than 2% renal elimination.
Category C
Category C
Antifungal
Antifungal